Oppenheimer Starts Entrada Therapeutics (TRDA) at Outperform, 'Platform Company Targeting High Value Diseases
Tweet Send to a Friend
(Updated - January 4, 2024 4:04 PM EST)
Oppenheimer analyst Hartaj Singh initiates coverage on Entrada Therapeutics (NASDAQ: TRDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Hartaj Singh initiates coverage on Entrada Therapeutics (NASDAQ: TRDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
